JP2015501784A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501784A5
JP2015501784A5 JP2014540115A JP2014540115A JP2015501784A5 JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5 JP 2014540115 A JP2014540115 A JP 2014540115A JP 2014540115 A JP2014540115 A JP 2014540115A JP 2015501784 A5 JP2015501784 A5 JP 2015501784A5
Authority
JP
Japan
Prior art keywords
alkyl
disease
methyl
cycloalkyl
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014540115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501784A (ja
JP6005753B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/063235 external-priority patent/WO2013067296A1/en
Publication of JP2015501784A publication Critical patent/JP2015501784A/ja
Publication of JP2015501784A5 publication Critical patent/JP2015501784A5/ja
Application granted granted Critical
Publication of JP6005753B2 publication Critical patent/JP6005753B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014540115A 2011-11-04 2012-11-02 治療の方法 Expired - Fee Related JP6005753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555650P 2011-11-04 2011-11-04
US61/555,650 2011-11-04
PCT/US2012/063235 WO2013067296A1 (en) 2011-11-04 2012-11-02 Method of treatment

Publications (3)

Publication Number Publication Date
JP2015501784A JP2015501784A (ja) 2015-01-19
JP2015501784A5 true JP2015501784A5 (enExample) 2015-12-24
JP6005753B2 JP6005753B2 (ja) 2016-10-12

Family

ID=48192800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540115A Expired - Fee Related JP6005753B2 (ja) 2011-11-04 2012-11-02 治療の方法

Country Status (11)

Country Link
US (2) US9242962B2 (enExample)
EP (1) EP2773754B1 (enExample)
JP (1) JP6005753B2 (enExample)
KR (1) KR20140095073A (enExample)
CN (1) CN104039956A (enExample)
AU (1) AU2012332297B2 (enExample)
BR (1) BR112014010803A2 (enExample)
CA (1) CA2854447A1 (enExample)
ES (1) ES2600161T3 (enExample)
RU (1) RU2621148C2 (enExample)
WO (1) WO2013067296A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014100665A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
WO2015077194A1 (en) * 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015120372A2 (en) * 2014-02-10 2015-08-13 University Of Rochester Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases
KR20160122266A (ko) * 2014-03-07 2016-10-21 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
CN106132954B (zh) 2014-03-17 2019-01-08 第一三共株式会社 1,3-苯并二氧杂环戊烯衍生物
KR20170068603A (ko) * 2014-10-28 2017-06-19 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 제스트 인핸서 상동체 2 억제제
CN107249593A (zh) * 2014-11-06 2017-10-13 达纳-法伯癌症研究所股份有限公司 调节染色质结构的组合物用于移植物抗宿主疾病(gvhd)的用途
CN107105651A (zh) 2014-11-06 2017-08-29 达纳-法伯癌症研究所股份有限公司 Ezh2抑制剂及其用途
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
JP2018522045A (ja) * 2015-08-03 2018-08-09 コンステレーション・ファーマシューティカルズ・インコーポレイテッドConstellation Pharmaceuticals,Inc. Ezh2阻害剤および制御性t細胞機能の調節
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
CN105541801B (zh) * 2016-01-18 2018-07-17 常州大学 Ezh2甲基转移酶抑制剂gsk126的合成方法
CA3018270A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
EP3472166A1 (en) * 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
KR102351782B1 (ko) * 2016-09-07 2022-01-17 상하이 하이헤 파마수티컬 컴퍼니 리미티드 피리도 5원 방향족 고리계 화합물, 이의 제조 방법 및 용도
EP3529242A1 (en) 2016-10-19 2019-08-28 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技(上海)有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
CA3104209A1 (en) 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
TWI837231B (zh) 2018-11-29 2024-04-01 日商第一三共股份有限公司 含有ezh1/2雙重抑制劑之醫藥組合及其用途
JP2022514353A (ja) * 2018-12-21 2022-02-10 ザ ウォルター アンド イライザ ホール インスティテュート オブ メディカル リサーチ 炎症の治療方法
CN113773304B (zh) * 2019-02-25 2023-03-10 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法
CN111961034A (zh) * 2019-05-20 2020-11-20 浙江同源康医药股份有限公司 用作ret激酶抑制剂的化合物及其应用
JP7721501B2 (ja) 2019-07-31 2025-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cd38の阻害剤としてのヘテロ二環式アミド
JP2022545467A (ja) 2019-08-22 2022-10-27 ジュノー セラピューティクス インコーポレイテッド T細胞療法とzesteホモログ2エンハンサー(EZH2)阻害剤との併用療法および関連方法
PH12022551578A1 (en) * 2019-12-25 2023-11-29 Nippon Shinyaku Co Ltd Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
MX2023008701A (es) 2021-01-29 2023-11-29 Boehringer Ingelheim Int Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2584713B1 (fr) 1985-07-11 1988-09-09 Roussel Uclaf Nouveaux derives de l'indole carboxamide, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
CN1929834B (zh) * 2004-03-11 2010-12-08 埃科特莱茵药品有限公司 吲哚-1-基乙酸衍生物
WO2007053114A1 (en) * 2005-10-31 2007-05-10 S*Bio Pte Ltd Method of predicting a response to hdac inhibitors
WO2008109534A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2009006577A2 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
CN102369204A (zh) 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
WO2010051550A1 (en) * 2008-10-31 2010-05-06 University Of Rochester Methods of diagnosing and treating fibrosis
KR20120046099A (ko) * 2009-02-04 2012-05-09 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 섬유화를 억제하고 섬유화 질병을 치료하는 방법
ES2534804T3 (es) 2010-05-07 2015-04-28 Glaxosmithkline Llc Indazoles
HRP20170736T1 (hr) * 2010-05-07 2017-07-28 Glaxosmithkline Llc Indoli
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
EP3323820B1 (en) * 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2015501784A5 (enExample)
EP2549875B1 (en) Soluble guanylate cyclase activators
JP6215338B2 (ja) キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
EP2789615B1 (en) Azaindazoles as Btk kinase modulators and use thereof
CA2934137C (en) Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments
US10428044B2 (en) 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
AU2014373735B2 (en) Therapeutic inhibitory compounds
AU2005259894C1 (en) Pyrrolotriazine kinase inhibitors
EP2566477B1 (en) Amino-quinolines as kinase inhibitors
WO2016011390A1 (en) Irak4 inhibiting agents
CA2803842A1 (en) Nicotinamide derivative or salt thereof as syk-inhibitors
HK1217482A1 (en) Enzyme modulators and therapies
EP3568390A1 (en) Small molecule activators of nicotinamide phosphoribosyltransferase (nampt) and uses thereof
JP2013528591A5 (enExample)
WO2009027283A1 (en) Triazolopyridine compounds and their use as ask inhibitors
CN103702979A (zh) 含亚磺酰亚胺基团的4-芳基-n-苯基-1,3,5-三嗪-2-胺
MX2015004151A (es) Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
AU2005292152A1 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
JP2009517383A (ja) 新規な3−ビシクロカルボニルアミノピリジン−2−カルボキサミド又は3−ビシクロカルボニルアミノピラジン−2−カルボキサミド
WO2013067300A1 (en) Method of treatment
AU2005300736B2 (en) Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
KR20150135794A (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 phd의 저해제로서의 그의 용도
KR20170044204A (ko) 오렉신―1 수용체의 억제제로서의 치료 화합물
MX2010013549A (es) Imidazoles sustituidos con 2-piridilo, como inhibidores de alk4 y/o alk4.
EP3600312B1 (en) Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6